Superluminal secures $60M for Phase 1 of genetic obesity drug
Superluminal Medicines raises $60 million to advance its genetic obesity drug candidate into Phase1clinical trials.
Superluminal Medicines
Private
Superluminal Medicines is a biotechnology company developing medicines for genetic obesity. The company has secured $60 million to advance its lead program into Phase 1 clinical trials.
Company Info
Sector:Obesity / Metabolic Diseases
Headquarters:United States
Founded:2022
Website:www.superluminalrx.com/